This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

1State Key Laboratory of Genetic Engineering, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Cancer Institutes, Shanghai, ...

Institute of TCM-X/MOE Key Laboratory of Bioinformatics, Bioinformatics Division, BNRist/Department of Automation, Tsinghua University, Beijing, China.

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

1Krantz Family Center for Cancer Research, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.

Mol Cancer Ther (2024) 23 (11): 1515.

In preliminary results from the phase II iMMagine-1 trial released today, the BCMA-directed chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel (anito-cel) did not elicit any ...

1Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, New York.

1Catholic University of the Sacred Heart and Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy. Search for other works by this author on: 2Department of Oncology, Sidney Kimmel ...

1Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China. 2Breast Tumor ...

Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University ...